N-Acetylgalactosamine



Compound IDCDAMM01364
Common nameN-Acetylgalactosamine
IUPAC nameN-[2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
Molecular formulaC8H15NO6

Experimental data

Retention time7.97
Adduct[M+K]+
Actual mz260.052
Theoretical mz260.053
Error5.61
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.7844

Identifiers and class information

Inchi keyOVRNDRQMDRJTHS-RSFXFOPENA-N
SmilesO=C(NC1C(O)OC(CO)C(O)C1O)C
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)2
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)1
Number of rotatable bonds (#rotor)6
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)221.21
Computed dipole moment(dipole)7.218
Total solvent accessible surface area (SASA)431.868
Hydrophobic component of SASA (FOSA)213.21
Hydrophilic component of SASA (FISA)218.658
Pie component of the SASA (PISA)0
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)703.907
Number of hydrogen bond donors (donorHB)5
Number of hydrogen bond acceptors (accptHB)11
Free energy of solvation of dipole (dip^2/V)0.0740226
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0569543
Globularity descriptor (glob)0.886115
Predicted polarizability in cubic angstroms (QPpolrz)18.164
Predicted hexadecane/gas partition coefficient (QPlogPC16)7.424
Predicted octanol/gas partition coefficient (QPlogPoct)19.829
Predicted water/gas partition coefficient (QPlogPw)21.462
Predicted octanol/water partition coefficient (QPlogPo/w)-2.582
Predicted aqueous solubility (QPlogS)-0.285
Conformation-independent predicted aqueous solubility (CIQPlogS)0.238
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-2
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)46.364
Predicted brain/blood partition coefficient (QPlogBB)-1.655
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)33.85
Predicted skin permeability, log Kp (QPlogKp)-4.973
PM3 calculated ionization potential (IP(ev))9.85
PM3 calculated electron affinity (EA(eV))-0.98
Number of likely metabolic reactions (#metab)3
Prediction of binding to human serum albumin (QPlogKhsa)-1.311
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)41.651
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)32.184
Van der Waals surface area (PSA)132.699
Number of nitrogen and oxygen atoms (#NandO)7
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
P16278GLB1Beta-galactosidase (by homology)T73134SEA
Q9BZP6CHIAAcidic mammalian chitinase (by homology)T51597SEA
P32320CDACytidine deaminase (by homology)T79027SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
O60502OGABifunctional protein NCOATT19567SEA
P52789HK2Hexokinase type IIT96685SEA
P01112HRASTransforming protein p21/H-Ras-1T71081SEA
P17931LGALS3Galectin-3T72038SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P06865HEXABeta-hexosaminidase subunit alphaT63196SEA
P07686HEXBBeta-N-acetyl-D-hexosaminidase-A/BT63197SEA
P09382LGALS1Galectin-1T09544SEA
Q07108CD69Early activation antigen CD69T48780SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T73134DI0242Lysosomal disease[ICD-11: 5C56]P16278GLB1
T79027DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P32320CDA
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T19567DI0025Alzheimer disease[ICD-11: 8A20]O60502OGA
T19567DI0331Parkinsonism[ICD-11: 8A00]O60502OGA
T96685DI0133Epidermal dysplasias[ICD-11: EK90]P52789HK2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T63196DI0242Lysosomal disease[ICD-11: 5C56]P06865HEXA
T63197DI0242Lysosomal disease[ICD-11: 5C56]P07686HEXB

Copyright © 2025